<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">Recent randomized trials have reported improvements in progression-free and overall survival with aggressive treatments directed at oligometastases [
 <xref ref-type="bibr" rid="CR12">12</xref>–
 <xref ref-type="bibr" rid="CR15">15</xref>], including stereotactic ablative radiotherapy (SABR). The application of ablative therapies for patients with 4–10 metastatic sites is being evaluated in the randomized phase III COMET-10 trial [
 <xref ref-type="bibr" rid="CR16">16</xref>] where patients are randomized to ablative SABR to all sites of disease versus standard of care treatment.
</p>
